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There are three major types of blood cancer that can attack a victim at any age: Leukemia, 
Lymphoma, and Myeloma.  Leukemia is a type of cancer that is found in blood and bone marrow 
and is caused by a rapid production of abnormal white blood cells.1  There are four broad 
classifications of leukemia: acute lymphocytic leukemia, acute myelogenous leukemia, chronic 
lymphocytic leukemia, and chronic myelogenous leukemia.2  Lymphoma is a growth of 
abnormal lymphocytes in the lymphatic system and is divided into two major categories: 
Hodgkin lymphoma and non-Hodgkin lymphoma.3  Finally, Myeloma is a cancer of the plasma 
cells, and prevents the normal production of antibodies, limiting the body’s immune system.4   
 
THE LEUKEMIA & LYMPHOMA SOCIETY STORY 
 
Robert Roesler de Villiers died at the age of 16 in 1944 to leukemia after a brief battle with 
ineffective treatments. Robert was the son of a wealthy New York family, who, after five years 
of mourning their son, started a fundraising and education organization in Robert’s name. At first, 
the Robert Roesler de Villiers Foundation was small and faced a daunting enemy since most 
leukemia patients were dying after three months of battling the disease.5 This organization 
concentrated on a disease with a 100% fatality rate with a tiny budget and was the predecessor to 
the Leukemia Society of America. In 2000, the organization transitioned from the Leukemia 
Society of America to the Leukemia & Lymphoma Society.  During the transition, the firm 
restructured “some of the large metropolitan area chapters to be more responsive to the 
communities” it served by “centralizing their activities and sharing their resources.”6 
 
Today, the Leukemia & Lymphoma Society (LLS) is headquartered in White Plains, New York, 
with a network of chapters in the United States and Canada.7 LLS is a nonprofit organization that 
relies on the generosity of individual and corporate contributions to fund research, patient 
services, professional and patient education, and representation of patients’ healthcare concerns 
and medical research interests to government policy makers.  
 
The firm promotes itself to be the world’s largest voluntary health organization dedicated to 
funding blood cancer research, and also provides education and patient services. Since it was 
founded in 1949, LLS has invested more than $750 million in research specifically targeting 
blood cancers.  Additionally, in 2011, LLS made more than 7.1 million contacts with patients, 
caregivers, and healthcare professionals through its Information Resource Center.8 Through 
support and research, the organization has helped to nearly quadruple “the relative five-year 
survival rate for people with leukemia” 9 and reclassify Hodgkin lymphoma as “one of the most 
curable forms of cancer.”10 
 
STRATEGIC DIRECTION 
 
“Nonprofit management is unique because nonprofit organizations are reliant on the support of 
donors and the work of volunteers, pursuing missions derived from values and principles about 
which there may be disagreement… among multiple constituencies both inside and outside the 
walls of the organization itself.”11  In addition, the performance of a non-profit firm’s board of 
directors is measured against the societal mission. Therefore, non-profit executives must manage 
the double-bottom line of societal and financial performance.  This fundamentally differs from 
businesses that are evaluated against free market forces and aligned by a profit generating value 
proposition.12 Exhibit 1 provides a value chain breakdown for LLS.
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John Walter joined LLS in 1995 and has been the organization’s President and CEO since 2008. 
He is tasked with achieving LLS’s double bottom line.  As the Senior Vice President of Finance 
and Information Technology, he centralized all finance and treasury operations in 1999, leading 
to a more efficient and stronger organization.  “As Executive Vice President of Strategic 
Alliances and New Business Development, Walter designed and implemented LLS’s Co-Pay 
Assistance Program, a service that helps blood cancer patients with their health insurance 
premiums and prescription drug co-pays.”13  With over 30 years of experience, he continues to 
build a strong foundation in his current role of leading LLS.  “Walter is stewarding LLS in its 
efforts to accomplish goals set forth in its strategic plan, including: developing a culture of 
superior volunteers and staff; diversifying LLS's revenue sources; advancing the development of 
new blood cancer therapies; and ensuring that all blood cancer patients have access to 
information and services that help them throughout their cancer journey.”14 
 
The mission of The Leukemia & Lymphoma Society (LLS) is to “cure leukemia, lymphoma, 
Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.”15  
As the world's largest voluntary health agency dedicated to blood cancer, LLS funds lifesaving 
blood cancer research around the world and provides free information and support services.  
Through its mission and list of Key Priorities, The Leukemia & Lymphoma Society helps blood 
cancer patients live better, longer lives.   
 
LLS’s priorities target advancing the societal mission and achieving financial efficiency. In order 
to advance the diagnosis and treatment of patients with blood cancer, LLS balances resources by 
prioritizing research, education, and advocacy.  Research funding is provided through to 
academia, the Therapy Acceleration Program, and other special initiatives. Information and 
services are distributed nationally and locally for patients throughout their cancer journey 
worldwide. Finally, the Office of Public Policy functions to remove barriers to patient care.   
 
In order for the firm to achieve the greater societal goals, LLS also works towards operational 
efficiencies in the fundraising, technology, and human resources. It enables its mission by 
retaining and establishing new income streams across United States and Canada through 
volunteer engagement and donor pipeline.  Priorities for IT include solutions to streamline 
operations.  Lastly, the firm achieves its mission through employee and volunteer talent 
acquisition and engagement. 
 
LLS Boards 
 
“Non-profit boards are often larger, have more committees, and have a very different board 
member lifecycle.”16 LLS has three organized boards: Board of Directors (BOD), Medical and 
Scientific Advisory Board (MSAB) and Board to Trustees (BOT).  Each has its own mission and 
direction that align and support LLS’s mission.   
 
“The Board of Directors is the ultimate governing authority of The Leukemia & Lymphoma 
Society.  Its mission is to govern the organization, protect the organization's image and assets, 
and provide leadership in the fight against blood cancers.”17 Supporting the BOD, there are five 
standing committees who govern the work of the board and six operating committees who 
perform “high-level mission-related work and are heavily dependent on volunteers.”18  The BOD 
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are responsible for the “oversight of LLS’s financial, ethical and legal affairs and ensure the 
organization’s stability and viability. Approve the annual operating and capital plans as well as 
monitor progress against goals and program effectiveness, and promote a culture of 
accountability for results.”19 
 
The Medical and Scientific Advisory Board’s responsibility is “to further LLS’s mission by 
fostering scientific discoveries and medical advances in blood cancers.”20   The proposed 
research grants are reviewed by MSAB, which is comprised of volunteer health professionals 
who are leading experts within their fields.  A subcommittee reviews the requests for quality and 
relevance to the LLS mission.  MSAB then creates a funding recommendation based on the 
overall scientific quality of applications and funds available.  The final recommendations are 
presented to the Mission Oversight Committee for final approval. 
 
The Board of Trustees is based on the local level at each chapter level.  The local BOT’s are 
comprised of volunteers who serve as ambassadors to LLS to help promote events locally, and 
help recruit sponsors for the organization.  “Their mission is in line with the LLS mission, cure 
leukemia, lymphoma, myeloma and improve the quality of life of patients and their families.”21  
 
Chapters 
 
The LLS organizational model is one of a goal seeking system where “the various parts of the 
association work in coordinated fashion to achieve common system wide goals.” 22  This is a top-
down corporate structure in which the chapters rely on the central office to establish an overall 
plan and to guide organizational actions.  Authority can “be delegated from the center to the 
local members for efficiency reasons” because “all members are assumed to be working in 
coordinated fashion.”23 
 
Branching out from the centralized headquarters, LLS has several local chapters throughout the 
U.S. and Canada to provide local support and administer local events. Each individual chapter is 
staffed with a salaried executive director, campaign and services managers, and donor relations 
personnel to achieve the mission. 
 
The top down strategy at LLS is to assign fundraising and outpatient funding goals to each 
chapter based on number of participants and number of patients in the area in need of services.  
Each chapter must meet this fundraising goal while keeping a 75% margin on costs that is used 
for cancer research, education, advocacy, and patient services.24   The organization raises this 
money through numerous fundraising efforts around North America and Canada.25 
 
Centralized Functions  
	  
LLS has also centralized traditional organization functional groups in human resources, 
Information Technology (IT), and Finance.  Consistent with the organization message, these 
functional groups strive to do more with less through talent management, technology use, and 
financial reporting.  IT’s mission is to deliver superior services to LLS through its solutions and 
platforms, and to continue to execute plans in place and find new opportunities to partner with 
the business units. Human Resources is tasked with hiring, inspiring and retaining "A" talent for 
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all positions at LLS.  One of the goals of LLS is to transform the Human Resources department 
into a proactive service organization and to strengthen a performance-driven culture.  LLS hopes 
to achieve "best in class" level HR processes from on-boarding to out-placement, and to expand 
diversity from top to bottom.  The Finance department works to minimize labor-intensive 
transactions and transaction processing, and to greatly reduce staff time spent gathering, 
consolidating, forecasting and budgeting, actual and operational data.  The department also 
provides analyses and predictive models that help LLS solve problems, gain marketplace 
advantage, and support new initiatives. 
	  
Governance Issues 
 
The non-profit industry is unregulated and unaccountable to outsiders because of light regulation 
in most states and lack of stockholders.  This general lack of oversight can subject firms to 
agency problems stemming from excessive executive salaries or professional fees associated 
with operations.26 However, across the LLS organization, only $87.9 million in employee 
salaries and benefits, and $30.4 million in professional fees, were included in the 2011 
consolidated financial statements (See Exhibits 2-3).  The disclosure notes indicate that these 
professional fees include “fundraising counsel fees, data processing services, contracted software 
development, and legal and auditing fees.” 
 
REVENUE STRATEGIES 
 
Fundraisers must develop a funding model to sustain growth and focus the organization to 
efficiently develop revenue streams.  Small organizations may have success with charismatic 
leadership being the key to “inspiring a handful of donors, seizing unanticipated funding 
opportunities, or cobbling together a mixed bag of funding sources.”27  However, in order to 
achieve scale and reach $50 million in annual revenue, the majority of non-profit organizations 
“got big not by diversifying their funding sources but by raising most of their money from a 
single type of funding (such as corporations or government) that was a natural match for their 
mission. Moreover, they created professional organizations tailored to the needs of that type of 
funding.” 28 
 
Central to LLS’s revenue generation strategies is George Omiros. Omiros has dedicated the 
majority of his career to LLS, starting in 1988. He took his current position of Executive Vice 
President of Campaign and Field Development in June of 2012.  With almost 25 years of 
commitment to LLS, George has impacted the organization through various positions such as 
Executive Director of a local chapter, National Marketing Representative, National Director of 
Major Gifts, National Director of Community Campaigns and National Director of Federated 
Campaign.  “George now provides strategic direction and overall management of LLS's chapters 
and their campaign activities, including LLS core campaigns: Team In Training, Light The Night 
Walk, Man & Woman of the Year and School & Youth programs in the United States and 
Canada.”29 
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Fundraising	  
Fundraising is a large organizational function of LLS.  Fundraising includes money and time 
targeting both corporate and individual contributors. LLS’s fundraising strategy targets small 
individual donors by using a heartfelt-connection model through large health-centered events.  
LLS sponsors many sources to raise money, including: “Team in Training”; “Light the Night 
Walk”; “Man & Woman of the Year”; “School & Youth Programs”; Leukemia Cup Regatta”; 
“Make Cures Happen”; and many other golf, BMX, media, and funding events.  LLS also 
partners with corporate sponsors to fund patient programs, license logos, and sell products. 
Team in Training was created 23 years ago, and it has grown “to be the world’s largest and most 
successful endurance sports charity training program.”30  More than 570,000 people have raised 
a total of $1.3 billion participating in the Team in Training program by competing and 
completing a marathon, half marathon, triathlon, or century ride.31  Team in Training (TNT) 
members choose from over 200 accredited international events in which they will compete and 
raise a requisite amount of money in order to both provide revenue to LLS and cover the team 
member’s event costs.32 Stakeholders for Team in Training include the sponsors who donate 
money to the participants, the participants who raise money for the Leukemia and Lymphoma 
Society, and the recipients of that money raised.33   
 
In order to drive commitment and personnel connection, LLS positions its mission through the 
program. “The Leukemia and Lymphoma Society’s Team in Training, for instance, starts each 
Saturday morning walk or run with a ‘dedication.’  A cancer survivor, someone who has the 
disease currently, a researcher, or a Team in Training participant will tell his or her own story 
before the trainees embark on their exercise session.”34 
 
Events like races are a positive venue for raising money and condition awareness, while 
participants are inspired to train harder knowing their event is to raise money for that condition.35  
“Knowing that your increased physical activity could help find a cure for breast cancer, leukemia, 
arthritis, or some other debilitating…condition certainly helps heighten commitment to an 
exercise program.”36  
 
Light the Night Walk funds research and support for cancer patients largely through corporate 
fundraising teams.37  The fundraising teams, which can be organized amongst friends, families, 
and corporations, participate in an evening walk in the fall of each year, and influence millions of 
consumers to donate at retail outlets across the country.38 
 
School & Youth Programs throughout North America organize students in 27,000 registered 
schools to participate and raise money for smaller programs such as Pennies for Patients, Olive 
Garden’s Pasta for Pennies, HOP for Leukemia & Lymphoma, and the Trish Greene Back to 
School Program for the Child with Cancer.39  These organizations have raised $29 million 
through the 2011-2012 school year and School & Youth Programs have raised more than $200 
million since its inception.40  
 
The Man & Woman of the Year campaign is a ten-week campaign to fundraise for cancer 
research.41  The male and female candidates “who raise the most funds during the campaign will 
be awarded the title of the chapter’s Man and Woman of the Year, respectively.”42  The 
Leukemia Cup Regatta is an annual boating competition held to raise money for cancer 
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research.43  Skippers register boats for the event, and recruit friends and colleagues to help crew 
and to raise funds.44 
 
Disconcerting for the Leukemia and Lymphoma Society, “gains of 1.3 million in new and 
previously lapsed donors were offset by losses of 1.4 million in lapsed donors.”45  Like many 
organizations that rely on return donors and participants, the number of donors and volunteers 
that stay on each year are declining.46  LLS’s division of Team in Training has had particular 
trouble in retaining race participants, as it overwhelmingly relies on return participants for its 
fundraising dollars.   
 
Financial Revenues 
	  
Sources of revenue for LLS include contributions, donated services, and investment income.  
Around 88%, or $314 million in 2011, of revenue is a result of campaign contributions or 
donations. External factors can drastically swing the revenue streams from fundraising 
contributions from year to year.  For example, revenue increased 13% between 2010 and 2011, 
but dropped -4% from 2009 to 2010.  Between 2007 and 2011, revenues have increased at a 2.8% 
annual growth rate.47  
 
Marketing 
 
Large organizations possess a fundraising advantage through marketing and positioning. In 2012, 
the Fundraising Effectiveness Project summarized fundraising effectiveness.  One of the findings 
stated that “Growth-in-giving performance varies significantly according to organization size 
(based on total amount raised), with larger organizations performing much better than smaller 
ones. Organizations raising $500,000 or more had an average 10 percent net gain. Organizations 
raising $100,000 to $500,000 had an average 0.8 percent net gain. Organizations in the under 
$100,000 groups had an average net loss of -9.6 percent.”48 Marketing of the organization is 
critical for nonprofit revenue generation and competition has even led to some charities taking 
legal action against other firms regarding messaging.  For example Susan G. Komen has 
protected the phrase “For a Cure” as their own. 
 
In order for charitable organizations to capture market penetration, “word of mouth is, by far, the 
most frequently cited source of information about charities.” According to Mintel 2009 Charities 
of Choice Report Survey, 43% of donors “stated that they learned about a charity from a friend 
or family member while only 14% stated they learned about a charity through an 
advertisement.”49 LLS marketing and positioning is focused on grassroots, word-of-mouth 
efforts and programs to reinforce the mission.  The organization does not fund centralized, 
national marketing campaigns.   
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External Forces Influencing Revenue Generation 
	  
All nonprofits, including cancer societies, are suffering from the recession.  “Many organizations 
continue to experience the effects of the recession, which has resulted in the reduction of badly 
needed resources.”50  First, there has been a large increase in the demand for nonprofit services, 
including for medical services such as cancer treatment and support, as medical patients find 
themselves unable to pay for expensive treatments and care themselves.51  Second, donor 
spending habits are impacted.  A study from the Nonprofit Research Collaborative shows that 
“nonprofits aren’t letting the slower trickle of donations get them down, and 63 percent of 
organizations surveyed anticipate contributions to them will increase….”52  There is conflicting 
research, however whether the nonprofits are able to bolster donations with evidence of 
increased demand for services, or whether they suffer along with their stakeholders in the midst 
of a recession.53 
 
Nonprofits rely on much-needed donations in the fourth quarter each year, usually a good 
prospect because the tax year is drawing to a close and the holidays encourage acts of goodwill.54  
“While unemployment stats in recent months have been better than expected, experts predict a 
difficult end-of-year climate for nonprofits….”55   
 
Political factors include the beneficial tax implications for donor groups. The Bush-era tax cuts 
are expiring and President Obama has mentioned the elimination of charitable giving tax breaks 
as a viable option for the budget crisis solution.56  The current structure is framed in the tax code 
under Charitable Contributions in IRS publication 526.57  “Qualified organizations include 
nonprofit groups that are religious, charitable, educational, scientific or literary in purpose, or 
that work to prevent cruelty to children or animals.”58  As it is easy to see, the Leukemia and 
Lymphoma Society falls into a number of these categories, and donors can deduct a lot of their 
charitable contributions to LLS throughout the year.59  If charitable deductions are removed from 
the list of tax deductions taxpayers enjoy each year, the potential outcome for nonprofits such as 
LLS could be devastating.60 
 
Disaster relief efforts also impact the LLS’s fundraising capability. While organizations that deal 
with disaster relief hopefully see a bump in donations, many of the other causes and issues will 
see donations pulled away to meet disaster relief needs.61 Charity transparency is also driving the 
choice of donor funds. Demand for proof of impact means that younger donors want to see more 
and more of the impact that their donation will make in an organization.62 They want to see more 
robust financial information and an impactful plan of attack from nonprofits. 
 
SPENDING STRATEGIES	  
 
Like all businesses, LLS has significant freedom to choose which activities to engage in. In 
contrast to business entities, non-profit firms do not create value for the firm when satisfying 
customers, but rather drain captured resources. “Management of a nonprofit organization 
requires constant trade-offs among the mission, the acquisition of resources, and strategy.” This 
contrasts with business and public sectors, that “while also complex, at least begins with some 
fixed points of clear goals and positive relationships between activities and revenues.”63  	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Dr. Louis DeGennaro has a lot of influence over how LLS spends its money. He started his 
career with LLS in 2005 and has held his current position of Chief Mission Officer since 2010.  
He has over 25 years of experience in the practice and management of science and has overseen 
projects that have impacted the lives of patients around the world.  “Dr. DeGennaro’s current 
responsibilities include oversight of all LLS mission functions: Public Policy, Patient Services 
and Research with the goal of effectively deploying resources in pursuit of the LLS mission.”64   
 
Research 
 
The organization works to proactively establish a research agenda and direct a spending to 
specific areas of unmet medical needs.  LLS participates directly in blood cancer therapy 
development by enabling research activities by academic collaborations, biotech partnerships, 
pharmaceutical companies, and venture capitalists. LLS does not perform any scientific activities, 
but attempts to influence scientific advancement through grants and awards.  The corporate 
office has four research award divisions:65 
 
Program Description 
Translational Research 
Program (TRP) 
This program is designed for innovative research with a high promise 
for advancing from basic biomedical knowledge to clinical application 
Specialized Center of 
Research (SCOR) 
This program supports collaborative research across at least 3 
integrated projects  
Career Development 
Program (CDP) 
This program offers stipends to researchers in order to participate in 
basic, clinical, or translational research 
Therapy Acceleration 
Program (TAP) 
This programs works with corporate partners to enable ‘proof of 
concept data’ during clinical drug development. 
 
Each research program has separate divisions and strategies within the segment.  The TRP, 
SCOR, and CDP are traditional research grant programs. Grants are initiated by electronic 
application from an external partner or scholar.  Each grant or award request is reviewed by a 
review panel that is specific for each division. The Medical & Scientific Affairs Committee then 
reviews the recommendations from each division’s review panel.  The Medical & Scientific 
Affairs Committee then presents a final research portfolio recommendation to the Mission 
Oversight Committee for approval.  The organizational decision making processes are unique for 
LLS because many of the process decision makers in the division review panels, Medical & 
Scientific Advisory boards, and Clinical Advisory Committees are comprised of volunteers from 
academic, healthcare, and corporate organizations.  This requires strong mission and values from 
the corporate office to align strategies of volunteer contributors. 
 
The Therapy Acceleration Program (TAP) serves as a facilitator between discovery and human 
applications for academic investigators, medical centers, and companies.  The goal is to increase 
the likelihood that novel and breakthrough treatments can be made available to patients sooner. 66 
To achieve this end, LLS works directly with corporate sponsors to speed up clinical trials for 
advancing therapies.   
 
  
	   9	  
TAP facilitates three innovative levels of research: 
• “The Academic Concierge Division identifies current LLS funded research with the 
greatest clinical promise and provides the funding and support needed to advance 
selected projects to the product stage 
• The Clinical Trials Division partners LLS with one of the country’s leading clinical-
trial centers to accelerate the testing of new blood cancer therapies in clinical trials 
• The Biotechnology Accelerator Division allies LLS with companies to combine 
scientific and financial resources and accelerate the development of potential 
therapies that otherwise would not be prioritized by the company.” 67 
 
Current partnerships with biopharmaceutical and pharmaceutical companies Baxter, Celgene, 
and other firms enable faster R&D return on investment. This enables businesses to move 
therapeutics forward into the marketplace by lowering internal profitability hurdles. 
 
The TAP project-review process “involves due diligence by an LLS staff team of drug 
development specialists in concert with a volunteer panel of leading biotechnology and 
pharmaceutical company executives and intellectual property and business development 
experts.”68	  
 
Patient Education and Services 
 
Through its different patient services programs, LLS has developed a services agenda for 
patients, their families, and health professionals to not only address their information and support 
needs, but also improve access to the latest individual therapy options and blood cancer clinical 
trials.  The programs are both national and local to help patients navigate diagnosis, treatment 
options, support groups, survivorship, clinical trials, and other matters around the disease 
specialties.  
 
Below is a summary of the specific resources at the corporate level:69 
• Information Specialists – Available online and over the phone, these masters level 
oncology professionals provide diagnosis and disease information guidance to patients.  
They also are able to conduct individual clinical trial searches. 
• TrailCheck – Through the LLS Website, visitors are able to locate clinical trial 
opportunities through the blood cancer specific clinical trial search tool. 
• Co-pay Assistance Program – Patients are able to apply to receive assistance to pay for 
drug co-pays and health insurance premiums.  Applications are handled via website or 
phone. 
• Telephone and Web Education Programs – LLS brings together patients, survivors, 
caregivers, and professionals with this series of educational programs that allows medical 
experts to share the most current disease, therapy, and research information. 
• LLS Website – Through the website, visitors are able to access new and archived 
educational programs, information, and content through a range of electronic formats.  
Additionally, the venue allows access to support groups, discussion boards, online 
disease management trackers, and other services and programs. 
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Below is a summary of the specific resources at the business/chapter level: 70 
• Family Support Groups - Volunteer oncology health professionals lead Family Support 
Groups to encourage communication among patients, families and health professionals.  
• Patti Robinson Kaufmann First Connection Program – Trained volunteers who are in 
remission are linked with patients with a similar diagnosis to share information and 
support. 
• Patient Financial Aid Program – “For more than 35 years, LLS has helped people who 
have blood cancer to cover a portion of their treatment costs.” 71 
• Trish Greene Back to School Program for Children With Cancer – The programs helps 
children, adolescents, and young adults transition from active treatment and return to 
school. 
 
Through the Information Specialists, website and local chapters, LLS distributes an extensive 
collection of free printed educational materials to patients, families, and healthcare professionals. 
 
Advocates  
 
The Office of Public Policy targets government and business decision makers to accelerate 
development and approval of new treatments and improve care access through equitable 
insurance reimbursement.  This group operates at both the state and national levels.  This group 
is also responsible for driving the LLS mission by increasing funding from non-LLS sources. 
Both salaried and volunteer employees are utilized. 
 
Through this function, “LLS successfully lobbied Congress in 2001 to institute a blood cancer 
research initiative as part of the U.S. Department of Defense medical research program. To date, 
that program has funded over $30 million in additional blood cancer research. In 2002, LLS 
successfully lobbied Congress for legislation that authorizes a new blood cancer research effort 
at the NCI and creates a new blood cancer education program for patients and the public under 
the Centers for Disease Control and Prevention (CDC). The patient education program was 
funded at $32 million through 2011, providing additional support for blood cancer patients and 
their families nationwide.”72 
 
In 2008, a cooperative research and development agreement, called The Learning Collaborative 
(TLC), between the University of Kansas Medical Center, Kansas City, The Leukemia & 
Lymphoma Society (LLS), the NIH Therapeutics for Rare and Neglected Diseases (TRND) 
program and the Hematology Branch within the National Heart, Lung and Blood Institute was 
“established as a shared commitment to move therapies for rare blood cancers into clinical proof-
of-concept studies so that promising treatments can eventually be commercialized.” 73 
 
Charitable Partnerships 
 
LLS partners with the Alliance for Childhood Cancer, Community Health Charities, Cancer 
Leadership Council, Friends of Cancer Research, One Voice Against Cancer, and 
Research!America to find new treatments and cures for blood cancers.74	   These organizations all 
rely on LLS dollars for research funding and patient care, and in return collaborate with LLS to 
help achieve LLS’s mission.  
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Financial Expenses 
 
LLS expense groups are split between program services, fundraising, and general management.  
Fundraising expenses and management expenses were 14% and 7% of revenue in 2011.  
Program services are further split into Research, Patient and Community Service, Public Health 
Education, and Professional Education. 
 
Table1: Expense % by category 2008 2009 2010 2011 
Research 28% 25% 26% 24% 
Patient and Community Service 28% 33% 31% 37% 
Public Health Education 15% 15% 16% 15% 
Professional Education 3% 3% 3% 3% 
Total Program Services 74% 76% 76% 78% 
 
Program services account for 78% of expenses and, as a measure of fundraising throughput, 
demonstrates increasing operational efficiency. Organizational salaries and administration 
expenses are still incurred as part of each of these category functions.  
 
Although the firm spent $299 Million in 2011, only 22.7%, or $67.8 Million, was spent on 
research through awards and grants, and the Therapy Acceleration Program.  Although this 
figure has increased over the last 3 years, it is still below 2007. Within the research budget, 
money is being shifting away from Awards and Grants and into the Therapy Acceleration 
Program.  In 2011, 25% of research dollars were spent in the program versus 3% in 2009 and 12% 
in 2010.  
 
The firm’s total payments to patients in 2011 were $43.5 Million through financial aid and co-
pay assistance.  Patient assistance has varied over the years, but in 2011 was over twice as large 
as the previous year.   
 
External Forces Influencing Spending 
 
Demand for nonprofit services has increased over the last four years, but the resources available 
to those in need are decreasing.  This is creating a bottleneck situation that is exacerbated by 
decreased funding to government social services as well.75 
 
Reimbursement for patient care impacts patient access to healthcare services. “2012 will mark 
the 15th consecutive year that the rate of growth for healthcare spending outpaces U.S. economic 
growth. For this reason, controlling healthcare costs remains a priority for policy makers, payers, 
and consumers.”76  Expensive new medical technologies, services, drugs, and medical equipment 
contribute to the rising costs. “Effective drugs, such as Avastin (from Roche Inc.) and Erbitux 
(Bristol-Myers Squibb) address previously untreatable lethal cancers, but they must be given 
over long periods of time and cost tens of thousands of dollars per year. 77  
 
LLS must depend on the pharmaceutical and biotechnology industries to advance research into 
commercial solutions.  Recently, the brand name pharmaceutical industry profits have been 
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under pressure from generic drug competition, pricing pressures from payers, and high R&D 
expenses. At the same time, the industry “has been experiencing a decline in R&D productivity, 
with a relative dearth of innovative new products launched in recent years.” 78  The industry is 
counting on improvements in early-stage product pipelines and an aging population to create 
future revenues and profits. 79   
 
While the pharmaceutical industry is dedicated to improving patient outcomes, the costs of drug 
development have become excessive. “Recent estimates of the attrition rate for compounds in 
oncology range from 77% to 92%, and the average cost of successfully developing a novel 
therapeutic, when failures are taken into account, is more than $800 million.”80 These complex 
compounds also prolong the development timelines and result in shorter periods of market 
exclusivity.81  The industry has responded with retrenchment initiatives, including reorganization 
of R&D operations. There is receptiveness to “forming alliances and making acquisitions with 
pipeline considerations in mind.”82 However, “critics say alliances between non-profit research 
hubs and Big Pharma give drug companies unfair advantage to research funded by public tax 
dollars.  Exclusive partnerships, they say, allow drug firms to cherry-pick among nonprofit 
institutes and advance only the drugs with potential profit for them onto the market.”83 
 
In order to increase industry collaboration in cancer research within corporations and academia, 
the government and pharmaceutical industry is working to establish better information sharing 
mechanisms. The National Cancer Institute’s cancer Bioinformatics Grid™ “initiative is a 
network of infrastructure and tools that enables the collection, analysis, and sharing of data and 
knowledge along the entire research pathway from laboratory bench to patient bedside.” 84 In 
2008, GlaxoSmithKline released “genomic profiling data for over 300 cancer cell lines” through 
the Grid in an attempt to enable “other cancer research institutions to save considerable drug 
development time and capital in their future cancer therapeutic research.”85 
 
Unfortunately, with the pharmaceutical industry moving towards collaborative research, 
intellectual property (IP) issues are being revealed that have not previously existed. “Although 
certain provisions of the U.S. Federal Acquisition Regulation (FAR) governing federal contracts 
address IP rights and ownership, the FAR does not clearly address scenarios where both federal 
and contractor employees work together on a project and are co-inventors of a resulting 
invention.” 86 In some cases these situations result in expensive lawsuits. 
 
Finally, regulatory hurdles also impact new cancer therapeutics from reaching the market.  First, 
increasing requirements for clinical data delay drug approvals through longer, more detailed 
processes of generation and agency review. Second, the process itself is not conducive to the 
multi-therapy treatments that oncology patients are commonly prescribed.87 Third, regulators 
further complicate treatment options by limiting use of approved drugs by also regulating 
marketing approvals.88 
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INDUSTRY COMPETITION 
 
The U.S. nonprofit industry includes 60,000 organizations with combined annual revenues of 
$100 billion.89  More specifically, the U.S. health fundraising industry consists of about 2,800 
organizations with combined annual revenue of about $16 billion.90  The 2012 Fundraising 
Effectiveness Survey Report, part of the Fundraising Effectiveness Project, “shows that the “net 
gain in giving” for charities responding to the survey in 2011 was $0”91 indicating growth in 
revenue is generated via market penetration. 
 
“The nonprofit and voluntary sector encompasses both professional, paid-staff nonprofit 
organizations as well as a larger and more diverse population of smaller, informal groups and 
grassroots organizations.”92  Major organizations with which, in a broader scope, LLS competes 
for revenue, include the American Cancer Society, Goodwill Industries, and the Bill & Melinda 
Gates Foundation.93  “Included in the industry are grant making foundations, charitable trusts, 
and other organizations that raise funds for social welfare activities; advocacy organizations that 
promote a particular cause or benefit a specific constituency; and groups that promote the civic 
or social interests of their members.”94  Nonprofits can be classified into service categories, with 
health as the largest segment of nonprofits, followed by education.95  For most nonprofits, 
fundraising is a major activity, as are grant applications, with direct mail solicitation and internet 
contributions being the two major sources of funds.96  One of the critical issues that impacts this 
industry segment is uncertain revenue, because nonprofits do not depend on product sales, and 
rely instead on the generosity of contributors.97  
 
Based on this description, the Leukemia and Lymphoma Society is working in a saturated market 
with many competitors.98  From large, formidable cancer organizations like Susan G. Komen and 
the American Cancer Society to smaller, local organizations like the Heart Connection and 
Mission4Maureen, LLS is in the peculiar position of having to compete against and work with 
other cancer organizations for a cure.99  In 2011, the Leukemia and Lymphoma Society was rated 
4th for best Cancer Nonprofit organizations, behind Susan G. Komen for the Cure (1), American 
Cancer Society (2), and LIVESTRONG.org (3).100 
 
American Cancer Society 
 
“The American Cancer Society, Inc. (ACS) is the nationwide, community based, voluntary 
health organization dedicated to eliminating cancer as a major health problem by preventing 
cancer, saving lives from cancer, and diminishing suffering from cancer through research, 
education, advocacy, and service.”101  Founded in 1913, it is now the largest voluntary health 
organization.  ACS is dedicated to eliminate cancer by “helping people stay well, helping people 
get well, by finding cures, and fighting back.”102  “More than two million volunteers carry out 
the Society's mission of eliminating cancer and improving quality of life for those individuals 
facing the disease.”103 
 
Headquartered in Atlanta, Georgia, ACS is supported by 12 chartered divisions that have over 
900 local offices within those regions.  The corporate office is responsive for overall strategic 
planning, corporate support services, and development and implementation of global and 
nationwide endeavors.104  Its local offices are tasked with educating the community, growing 
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support for programs, and raising money locally.  With over three million volunteers, ACS 
deploys a grassroots marketing campaign depending heavily on the dedication and goodwill of 
people to gain the support needed.  In addition to the $148.5 million invested in research in 
2011,105 “ACS supports detection, treatment, and education programs. The organization 
encourages prevention efforts through its Quit for Life antismoking campaign and the 
International Relay For Life. Patient services include moral support, transportation to and from 
treatment, and camps for children who have cancer.”106 
 
The local chapters are responsible for holding their own programs as well as the national 
programs.  These national programs include spreading awareness through campaigns as well as 
through athletic events.  ACS is recruiting volunteers to get involved in the Cancer Prevention 
Study – 3 (CPS-3) and through the Great American Smokeout.  By far, ACS’s greatest successes 
in raising money and awareness have been through the athletic events such as Making Strides 
Against Breast Cancer, DetermiNation, Relay For Life, and Coaches vs. Cancer.  These events 
and other sources generated total revenue of $953 million in 2011.107 
 
Susan G. Komen for the Cure 
 
Founded in 1982, Susan G. Komen for the Cure (SGK) promises “to save lives and end breast 
cancer forever.”108  Since its foundation, SGK has invested almost $2 billion in its search for a 
cure, including investing over $685 million in research and $1.3 billion in community programs. 
109  Annual revenues in 2011 were $438 million.110  SGK has the support of more than 75,000 
volunteers within 120 affiliates with a headquarters in Dallas Texas.111  With its dedication and 
contributions, SGK has assisted in earlier detection and effective treatment, more hope, more 
research and more survivors.112 
 
SGK relies on its grassroots efforts to help fulfill its promise of saving lives and ending breast 
cancer “by empowering people, ensuring quality care for all and energizing science to find the 
cures.”113 The global headquarters has been dependent upon its affiliates to help with the 
successes of its global events.  Through events like Komen Race for the Cure, Susan G. Komen 
3-Day for the Cure, and Marathon for the Cure, SGK has impacted the lives of not only women 
but men as well.  Its signature event, Komen Race for the Cure, by far its largest event, is hosted 
on five continents with over 1.7 million participants yearly.114   
 
Lymphoma Research Foundation 
 
“The Lymphoma Research Foundation (LRF) is the nation's largest non-profit organization 
devoted exclusively to funding innovative lymphoma research and providing people with 
lymphoma and healthcare professionals with up-to-date information about this type of cancer. 
LRF's mission is to eradicate lymphoma and serve those touched by this disease.”115  Like many 
nonprofits, LRF was formed by the merger of two organizations in 2001, Cure for Lymphoma 
Foundation and the Lymphoma Research Foundation of America.  With its focus on finding a 
cure for lymphoma only, LRF has awarded over $47 million in research grants. Annual revenues 
in 2011 were $11.7 million. To oversee the research grants, LRF has a Scientific Advisory Board 
with 45 volunteere experts who are also supported by the Board of Directors as well as the 
Senior Leadership Team. Its annual gala is by far its largest event, but LRF but depends 
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primarily on its 18 chapters and 5,000 volunteers to raise funds and promote its programs and 
services. 116 
 
Leukemia Research Foundation 
 
As a direct competitor to LLS, the Leukemia Research Foundation (LeRF) is also attempting “to 
conquer leukemia, lymphoma, and myelodysplastic syndromes by funding research into their 
cause and cures, and to enrich the quality of life of those touched by these diseases.”117  Annual 
revenues in 2011 were $1.98 million.118  Since its foundation in 1946 it has raised over $52 
million with assistance from 23 chapters and over 1,500 volunteers.  Working as a smaller 
foundation, it depends solely on the local chapters to host events to raise awareness and funds 
with no national events held.  To set itself apart LeRF “exclusively funds New Investigators - 
individuals who are beginning to establish their own laboratories and are no longer under the 
tutelage of a senior scientist mentor.”119  The research grants are awarded based on the expert 
recommendations from a Medical Advisory Board.  The board bases their recommendations on 
innovation of the proposal, mission of what affect the study may have and training / environment 
of the applicant.120 
 
CONCLUSION 
 
Born after the death of one sixteen-year-old teenager, the Leukemia & Lymphoma Society is 
built on goal-setting among chapters and at headquarters.  The organization uses sporting events 
and key fundraising programs to raise millions of dollars for the research of cures for blood 
cancer and for the patient care of millions of blood cancer victims.   
 
Much like for-profit firms, definition, alignment, and articulation of the organizational mission 
and values across different internal and external stakeholders is a critical management issue. 
Strategic implementation demands alignment and accountability of the organization through all 
the different divisions, chapters, and partners. However, LLS has multiple divisions and offices 
and heavily relies on volunteers throughout the organization. The fractionalized diverse set of 
contributors adds complexity to align the workforce and brings unique challenges to oversight 
and governance.  Additionally, the organization’s mission to help patients with blood cancers 
through support and advancement of treatment options is not conducive to traditional financial 
measurements.  
 
As in any organization, revenue growth and business efficiency are management priorities. LLS 
relies on charitable giving of donors and therefore, external forces and industry competition 
impact the ability to grow existing revenue sources.  Positioning and image of the organization 
itself is critical to revenue generation. Additionally, watchdog organizations continually monitor 
the effectiveness of organizations’ expenses for revenue generation. While LLS has a traditional 
fundraising mechanism of using large events to capture campaign contributions, the mechanism 
for additional revenue generation and growth is a critical strategic issue.  
 
Finally, a key function for LLS is advancing treatment options through research investment.  
Therefore, return on R&D investment is a critical issue.  Much like a pharmaceutical company, 
LLS must manage the research project portfolio and correctly resource projects that have 
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promise to reach clinical drug development.  However, without internal resources, LLS must not 
only rely on outside stakeholders to determine which projects to fund, but LLS also relies on 
external partners to advance projects through the drug development process. Additionally, the 
large intellectual property value of independent research can lead to isolation of research groups.  
Therefore, LLS must enable and influence collaboration across research organizations.   
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EXHIBIT 1: ORGANIZATION VALUE-CHAIN BREAKDOWN  
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EXHIBIT 2: CONSOLIDATED FINANCIAL STATEMENTS–BALANCE SHEET (000s) 
 
Assets 2008 2009 2010 2011 
Cash and Cash Equivalents  $36,180   $28,196   $21,196   $17,866  
Prepaid Expenses and other assets  $6,167   $4,389   $4,707   $5,171  
Legacies and contributions receivable, 
net  $7,167   $22,752   $18,417   $19,614  
Investments  $162,978   $161,623   $177,489   $181,876  
Fixed Assets  $5,148   $4,616   $5,132   $5,413  
Depreciation  $12,069   $12,544   $7,965   $8,606  
Amortization  $10,435   $12,069   $12,544   $7,965  
Total Assets  $217,640   $221,576   $226,941   $229,940  
     
Liabilities and Net Assets     
Liabilities     
Accounts Payable ad Accrued 
Expenses  $20,700   $14,682   $16,448   $17,715  
Deferred Revenue  $17,174   $15,479   $16,940   $17,241  
Grants Payable  $81,670   $85,768   $80,580   $71,579  
Total Liabilities  $119,544   $115,929   $113,968   $106,535  
     
Commitments and Contingencies     
     
Net Assets     
Unrestricted  $83,085   $78,551   $88,617   $95,108  
Temporary restricted  $11,932   $23,596   $20,668   $24,405  
Permanently Restricted  $3,079   $2,500   $3,688   $3,892  
Total Net Assets  $98,096   $105,647   $112,973   $123,405  
     
Total Liabilities and Net Assets  $217,640   $221,576   $226,941   $229,940  
 
Source: Leukemia Research Foundation, 2011. Leukemia Research Foundation Research Grant 
Funding Making an Impact Annual Report. Wilmette, IL: Leukemia Research Foundation.  
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EXHIBIT 3: CONSOLIDATED FINANCIAL STATEMENTS–INCOME (000s) 
 
Revenue 2008 2009 2010 2011 
Campaign contributions   $304,380   $291,521   $279,908   $314,044  
Less direct donor Benefits  $(42,541)  $(39,077)  $(36,635)  $(38,070) 
Net campaign contributions  $261,839   $252,444   $243,273   $275,974  
Legacies  $6,137   $26,459   $7,054   $7,736  
Donated Services  $5,740   $6,829   $6,819   $5,983  
Net Interest and dividend income  $7,204   $6,467   $4,430   $2,463  
Net increase in fair value of 
investments  $(4,839)  $(7,315)  $11,335   $15,283  
Grant refunds  $966   $2,768   $1,897   $1,748  
Total revenue  $277,047   $287,652   $274,808   $309,187  
     
Expenses     
Program Services     
Research  $76,979   $69,786   $70,910   $71,985  
Patient and Community Service  $77,686   $93,448   $83,406   $109,496  
Public Health Education  $42,094   $41,331   $41,597   $44,197  
Professional Education  $8,433   $8,497   $8,073   $7,979  
Total program services  $205,192   $213,062   $203,986   $233,657  
Supporting services     
Management and General  $24,942   $23,259   $22,462   $23,051  
Fundraising  $46,052   $43,132   $41,255   $42,367  
Total supporting services  $70,994   $66,391   $63,717   $65,418  
Total expenses  $276,186   $279,453   $267,703   $299,075  
     
Foreign Currency translation 
adjustment  $37   $(648)  $221   $320  
Change in net assets  $898   $7,551   $7,326   $10,432  
     
Net assets     
Beginning of year  $97,198   $98,096   $105,647   $112,973  
End of year  $98,096   $105,647   $112,973   $123,405  
 
Source: Leukemia Research Foundation, 2011. Leukemia Research Foundation Research Grant 
Funding Making an Impact Annual Report. Wilmette, IL: Leukemia Research Foundation.
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LUKEMIA AND LYMPHOMA SOCIETY 
 
DISCUSSION QUESTIONS 
 1. What are some of the special challenges managers face in not-for-profit enterprises? 2. Who are the Society’s customers and suppliers? Do these labels fit well in a not-for-profit firm? Can the same sorts of management techniques be applied in profit and not-for-profit firms? 3. What are the distinctive competencies of LLS? Do these competencies provide an advantage to the company or do their competitors also share these strengths? 4. One of the problems facing LLS is the retention of donors and participants. What are some of new ideas LLS could use to address this problems? 5. The case cites research that larger organizations are more successful in fundraising than small organizations, yet LLS has no national advertising campaign. Are they missing an opportunity? What are the advantages, if any, of only using local campaigns? 6. The case provides a lot of detail regarding the firm’s research grant and award process. Do you seen anything in their process that might be useful when applied to research in for-profit companies? 7. What can for-profit organizations learn from LLS regarding customer services? 8. What are some new ways LLS can raise funds for research and other purposes, beyond what they are already doing? 9. The pharmaceutical industry is looking forward to an aging population as a way to increase revenues and profits. Are there any ethical issues associated with this attitude? Is it acceptable to look forward to increased illness as a way to make money? 10. Are the other cancer fundraising organizations really competitors? If they are, then how should LLS develop strategies to beat them? If not, then what are they and how should LLS consider them when devising its strategies? 11. Should LLS consider a merger with another organization? If so, which one and why?  
